Literature DB >> 33550495

Rethinking Measurement Standards of Autism Symptomology in Adolescents with Fragile X Syndrome.

Heather Fielding-Gebhardt1,2, Shelley L Bredin-Oja3, Steven F Warren3,4, Nancy C Brady3,4.   

Abstract

Accurate representation of autism spectrum disorder (ASD) in fragile X syndrome (FXS) is necessary for the field. We examined classifications of ASD using three approaches-Autism Diagnostic Observation Schedule (ADOS-2; Lord et al. 2012), Childhood Autism Rating Scale (CARS2-ST; Schopler et al. 2010), and Vineland Adaptive Behavior Scales (VABS-II; Sparrow et al. 2005)-in 45 adolescents with FXS. Maladaptive items from the VABS-II plus a maternal interview were matched with Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5; American Psychiatric Association 2013) criteria for ASD. Results indicated discrepant classifications. The ADOS-2 yielded the highest rate of comorbid autism (71%); CARS2-ST and VABS-II/DSM-5 yielded lower rates (38% and 42%, respectively). A singular measure of autism symptomology is insufficient to characterize autism in FXS.

Entities:  

Keywords:  Autism; Fragile X syndrome; Measurement

Year:  2021        PMID: 33550495      PMCID: PMC8342619          DOI: 10.1007/s10803-021-04892-2

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  26 in total

Review 1.  Specific genetic disorders and autism: clinical contribution towards their identification.

Authors:  David Cohen; Nadège Pichard; Sylvie Tordjman; Clarisse Baumann; Lydie Burglen; Elsa Excoffier; Gabriela Lazar; Philippe Mazet; Clément Pinquier; Alain Verloes; Delphine Héron
Journal:  J Autism Dev Disord       Date:  2005-02

2.  The autism diagnostic observation schedule, module 4: revised algorithm and standardized severity scores.

Authors:  Vanessa Hus; Catherine Lord
Journal:  J Autism Dev Disord       Date:  2014-08

3.  Consistency between research and clinical diagnoses of autism among boys and girls with fragile X syndrome.

Authors:  J Klusek; G E Martin; M Losh
Journal:  J Intellect Disabil Res       Date:  2014-02-17

4.  Language in boys with fragile X syndrome.

Authors:  Yonata Levy; Riki Gottesman; Zvi Borochowitz; Moshe Frydman; Michal Sagi
Journal:  J Child Lang       Date:  2006-02

5.  Communication in young children with fragile X syndrome: a qualitative study of mothers' perspectives.

Authors:  Nancy Brady; Debra Skinner; Joanne Roberts; Elizabeth Hennon
Journal:  Am J Speech Lang Pathol       Date:  2006-11       Impact factor: 2.408

Review 6.  Language development and fragile X syndrome: profiles, syndrome-specificity, and within-syndrome differences.

Authors:  Leonard Abbeduto; Nancy Brady; Sara T Kover
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2007

Review 7.  Problem behavior in boys with fragile X syndrome.

Authors:  Deborah D Hatton; Stephen R Hooper; Donald B Bailey; Martie L Skinner; Kelly M Sullivan; Anne Wheeler
Journal:  Am J Med Genet       Date:  2002-03-01

8.  Developmental trajectories of young girls with fragile x syndrome.

Authors:  Deborah D Hatton; Anne Wheeler; John Sideris; Kelly Sullivan; Alison Reichardt; Jane Roberts; Renee Clark; Donald B Bailey
Journal:  Am J Intellect Dev Disabil       Date:  2009-05

9.  Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.

Authors:  Angela John Thurman; Andrea McDuffie; Randi Hagerman; Leonard Abbeduto
Journal:  Res Dev Disabil       Date:  2014-03-12

10.  Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization.

Authors:  Lisa Cordeiro; Elizabeth Ballinger; Randi Hagerman; David Hessl
Journal:  J Neurodev Disord       Date:  2010-12-03       Impact factor: 4.025

View more
  1 in total

1.  Maternal well-being and family adaptation during COVID-19 in fragile X syndrome.

Authors:  Heather Fielding-Gebhardt; Rebecca Swinburne Romine; Shelley Bredin-Oja; Nancy Brady; Steven F Warren
Journal:  Front Psychiatry       Date:  2022-08-23       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.